-
Understand diabetes and the diagnostic criteria for diabetes
Time of Update: 2022-11-26
8 mmol/L; Glycaemic control goals must be individualized (A); For patients with type 2 diabetes mellitus with other cardiovascular risk factors, comprehensive management measures such as hypoglycemia, blood pressure reduction, lipid regulation and aspirin therapy are recommended to prevent the occurrence of cardiovascular disease and diabetic microangiopathy (A).
-
WuXi Biologics and Japan's Toregem BioPharma signed a memorandum of understanding on the development of anti-USAG-1 antibodies
Time of Update: 2022-10-20
" " Dr. Zhisheng Chen, CEO of WuXi Biologics, said, "We are excited to be a partner of Toregem to accelerate the TRG035 development process through end-to-end services and professional insights, which is the first comprehensive project empowered by WuXi Biologics in the Japanese market from early-stage scientific research to clinical stage.
-
China Food and Drug Enterprise Quality and Safety Promotion Association escorts the development of food enterprises
Time of Update: 2022-09-16
Under the leadership of the State Food and Drug Administration, through conducting investigation and research, formulating industry development plans, releasing industry dynamic information and statistical analysis, proposing industrial development policy recommendations and assisting the government in macro-control, promoting industry technological innovation, and guiding industry brand building , participate in the formulation and revision of standards, build harmonious labor relations, carry out international exchanges and cooperation, strengthen industry training and self-discipline management, etc.
-
With the enthusiasm of pharmaceutical companies for research and development, the level of children's medication in China is constantly improving
Time of Update: 2022-09-08
For example, since 2008, the Health Commission has invested 600 million yuan through the special project of new drugs to support the research and development of children's drugs and clinical research; The National Children's Medical Center was established, and 23 pediatric medical institutions were united to establish the "China Pediatric Population Drug Clinical Trial Collaboration Network" to promote pediatric clinical trials.
-
What are the individualized treatments for HER2-mutant non-small cell lung cancer
Time of Update: 2022-06-01
A phase II clinical study showed that the objective response rate of 18 patients with HER2-mutated non-small cell lung cancer treated with TDM-1 was 44%, and the median progression-free survival was 5 months (Figure 3) [5] .
-
Ascletis Pharma's 2nd FASN Inhibitor Approved for Treatment of Advanced Solid Tumors
Time of Update: 2022-04-17
Article source: Medical Cube InfoA few days ago, CDE's official website showed that the clinical trial (IND) application of Ascletis' second fatty acid synthase (FASN) inhibitor ASC60 was approved by the Food and Drug Administration for the treatment of advanced solid tumors .
-
Lancet Neurol Annual Review: Epilepsy in Neurology Summary 2021
Time of Update: 2022-02-23
Subdural electrode assessment is more beneficial than SEEG for brain surgery in patients with drug-resistant epilepsy, but has more surgical complications and is less likely to be seizure-free .
-
O drug + chemotherapy significantly improves PFS in patients with such upper gastrointestinal tumors. The first update of "The Lancet" after Christmas is here
Time of Update: 2022-01-25
On January 11, a study investigating the efficacy of nivolumab + chemotherapy (oxaliplatin-based) versus placebo + chemotherapy in first-line treatment of patients with HER2-negative, unresectable advanced or recurrent gastric or gastroesophageal junction cancer Published in Lancet Oncol .
-
New Oral Alzheimer's Drug Obtains FDA Fast Track Qualification
Time of Update: 2022-01-10
Simcere Pharmaceuticals reached a $500 million cooperation with Vivoryon in June this year, and obtained the development and commercialization of two types of neurotoxic amyloid N3pE (pGlu-Abeta) in Greater China, including Varoglutamstat.
-
The Center for Drug Appraisal holds an expert seminar on hot topics in children's drug R&D
Time of Update: 2021-10-21
Kong Fanpu emphasized that enterprises are the main body of drug research and development and the core force to solve the problem of shortage of drugs for children in China .
-
Nature's in-depth analysis: China's new tumor drug "fast lane
Time of Update: 2021-06-10
Recently, with the reform of China's regulatory system, a series of accelerated drug development and review processes in China have been gradually introduced (Supplementary Table 1). These special re
-
The beet area may drop sharply and related support urgently needs follow-up
Time of Update: 2021-04-22
html" class="zdbq" title="Sugar-related food information" target="_blank">Sugar Competitive crops have obvious comparative advantages.
The increase in prices of major agricultural products such as corn drives up rents in the main sugar beet producing areas, and farmers' planting costs have increased rigidly.
-
The 2020 annual reports are coming out one after another
Time of Update: 2021-03-30
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>According to Corning Jereh’s 2020 full-year financial performance and company progress, the company’s important progress in 2020 are as follows: 1) The listing application for subcutaneous injection of PD-L1 inhibitor envolimab was obtained by the State Food and Drug Administration of China (NMPA) Accepted , the indication is microsatellite instability (MSI-H)/mismatch repair function defect (dMMR) advanced colorectal cancer, gastric cancer and other advanced solid tumors that have failed the standard treatment.
-
The top 5 best-selling gout drugs in pharmacies exposed to the first "siege
Time of Update: 2021-03-22
Sales of terminal anti-gout preparations in physical pharmacies in cities in China Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern In recent years, the market scale of terminal anti-gout preparations in Chinese urban physical pharmacies has been expanding, and the annual growth rate has remained at double digits.
-
Chinese scientists crack the drug-resistant genome of grass-greedy nightings
Time of Update: 2021-03-13
Sheng Jun, president of Yunnan Agricultural University, told science and technology daily that they had carried out genetic sequencing and analysis of grass-green nightingads and their drug resistance in cooperation with Huada Gene, Animal Institute and relevant institutions in the United States, South Africa, Ethiopia and Kenya.
